Revenue Breakdown
Composition ()
No data
Revenue Streams
Jazz Pharmaceuticals PLC (JAZZ) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Xywav, accounting for 38.3% of total sales, equivalent to $431.41M. Other significant revenue streams include Epidiolex/epidyolex and Rylaze. Understanding this composition is critical for investors evaluating how JAZZ navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Jazz Pharmaceuticals PLC maintains a gross margin of 73.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.88%, while the net margin is 22.33%. These profitability ratios, combined with a Return on Equity (ROE) of -9.06%, provide a clear picture of how effectively JAZZ converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, JAZZ competes directly with industry leaders such as MDGL and RGEN. With a market capitalization of $10.03B, it holds a significant position in the sector. When comparing efficiency, JAZZ's gross margin of 73.60% stands against MDGL's 93.69% and RGEN's 53.24%. Such benchmarking helps identify whether Jazz Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.
